Skip to main content

Table 1 Baseline participants characteristics

From: Association between triglyceride glucose index and adverse cardiovascular prognosis in patients with atrial fibrillation without diabetes: a retrospective cohort study

 

First group

Tyg ≤ 8.493

Middle group

Tyg 8.494–9.022

Third group

Tyg ≥ 9.023

P.value

 

N = 288

N = 288

N = 288

Mean age (SD), y

67.4 (14.2)

67.4 (14.3)

68.2 (13.2)

0.734

Male sex (%)

159 (55.2)

161 (55.9)

158 (54.9)

0.968

Paroxysmal AF (%)

158 (54.9)

166 (57.6)

173 (60.1)

0.449

Catheter ablation (%)

120 (41.7)

119 (41.3)

69 (24.0)

< 0.001

Weight (SD), kg

61.1 (12.5)

63.7 (13.5)

64.7 (13.0)

0.006

Unknown (%)

20 (6.9)

27 (9.4)

32 (11.1)

 

Height (SD), m

1.62 (0.09)

1.63 (0.09)

1.62 (0.09)

0.584

Unknown (%)

10 (3.5%)

19 (6.6)

17 (5.9)

 

Systolic pressure (SD), mmHg

130 (19.5)

129 (19.9)

129 (23.0)

0.733

Diastolic pressure (SD), mmHg

80.7 (13.7)

80.5 (13.5)

80.0 (14.7)

0.798

CHA2DS2-VASc (SD)

2.84(1.86)

2.82(1.92)

3.18(1.94)

0.038

Comorbidities (%)

    

Hypertension

150 (52.1)

133 (46.2)

145 (50.3)

0.346

Heart failure

86 (29.9)

95 (33.0)

118 (41.0)

0.015

Stroke/TIA

47 (16.3)

49 (17.0)

54 (18.8)

0.730

Systemic embolism

1 (0.4)

6 (2.1)

12 (4.2)

0.007

Coronary artery disease

60 (20.8)

59 (20.5)

85 (29.5)

0.015

Peripheral artery disease

25 (8.7)

13 (4.5)

17 (5.9)

0.114

COPD

33 (11.5)

23 (8.0)

30 (10.4)

0.361

Sleep disorders

11 (3.8)

14 (4.9)

9 (3.1)

0.559

Hyperthyroidism

4 (1.4)

10 (3.5)

1 (0.4)

0.014

Hypothyroidism

12 (4.2)

13 (4.5)

9 (3.1)

0.672

Laboratory tests:

    

GGT(SD), IU/L

48.8 (68.7)

52.3 (80.9)

77.2 (91.1)

< 0.001

Cholesterol (SD), mmol/L

3.76 (0.90)

3.99 (0.92)

4.29 (1.07)

< 0.001

LDL(SD), mmol/L

2.09 (0.74)

2.29 (0.78)

2.51 (0.92)

< 0.001

HDL(SD), mmol/L

1.31 (0.38)

1.18 (0.31)

1.04 (0.34)

< 0.001

SUA(SD), umol/L

336 (113)

365 (123)

404 (144)

< 0.001

SCR(SD), umol/L

93.4 (63.3)

98.3 (93.4)

132 (143)

< 0.001

NT-pro BNP(SD), ng/L

2313 (4073)

2588 (5052)

5841 (9057)

< 0.001

Unknown (%)

40(13.9)

29(10.1)

25(8.7%)

 

Echocardiogram data:

    

LAD(SD), mm

41.7 (8.72)

40.8 (7.84)

41.0 (7.64)

0.446

Unknown (%)

11(3.8)

19(6.6)

32(11.11)

 

LVD(SD), mm

48.3 (6.05)

47.7 (6.29)

49.5 (8.48)

0.010

Unknown (%)

12(4.2)

19(6.6)

32(11.11)

 

RAD(SD), mm

41.9 (8.71)

39.6 (8.18)

40.3 (7.78)

0.005

Unknown (%)

16(5.6)

28(9.7)

51(17.7)

 

RVD(SD), mm

22.4 (3.07)

22.0 (3.08)

22.0 (3.46)

0.302

Unknown (%)

12(4.2)

22(7.6)

45(15.6)

 

LVEF(SD), %

61.2 (10.4)

61.4 (11.3)

57.9 (14.1)

0.001

Unknown (%)

11(3.8)

20(6.9)

33(11.5)

 

Medications, %

    

OAC only

188 (65.3)

187 (64.9)

148 (51.4)

0.001

Antiplatelet only

23 (8.0)

24 (8.3)

28 (9.7)

0.736

OAC + Antiplatelet

20 (6.9)

21 (7.3)

24 (8.3)

0.806

ARNI/ACEI/ARB:

64 (22.2)

62 (21.5)

62 (21.5)

0.973

β-blocker:

80 (27.8)

93 (32.3)

95 (33.0)

0.341

Statin:

69 (24.0)

87 (30.2)

88 (30.6)

0.141

  1. Tyg: triglyceride glucose index; SD: standard deviation; AF: atrial fibrillation; CHA2DS2-VASc: heart failure, hypertension, diabetes, coronary artery disease/peripheral artery disease and female with one point each, one point for 65–74 years old, and two points for ≥ 75 years old, stroke/transient ischemic attack/systemic embolism with 2 points; TIA: transient ischemic attack; COPD: chronic obstructive pulmonary disease; GGT: glutamyl transpeptidase; LDL: low density lipoprotein; HDL: high density lipoprotein; SUA: serum uric acid; SCR: serum creatinine; NT-pro BNP: N-terminal pro B-type natriuretic peptide; LAD: left atrial anterior-posterior diameter; LVD: left ventricular maximum diameter; RAD: right atrial maximum diameter; RVD: right ventricular maximum diameter; LVEF: left ventricular ejection fraction; OAC: oral anticoagulation; ARNI: Angiotensin Receptor & Neprilysin Inhibitor; ACEI: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor blocker